SHEZF OTC
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
3Y: -34.8%
5Y: -67.8%
$0.47
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$17.3B
-9.7% ▼
5Y CAGR: +2.6%
Total Liabilities
$5.1B
-28.7% ▼
5Y CAGR: -7.9%
Shareholders Equity
$12.1B
+2.0% ▲
5Y CAGR: +10.6%
Cash & Investments
$2.6B
+12.9% ▲
5Y CAGR: +13.0%
Total Debt
$3.0B
-21.2% ▼
5Y CAGR: -13.9%
Net Debt
$1.3B
-33.2% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $2.7B | $2.9B | $2.1B | $1.9B | $1.7B |
| Short-Term Investments | $828M | $981M | $1.3B | $414M | $868M |
| Cash & ST Investments | $3.5B | $3.9B | $3.5B | $2.3B | $2.6B |
| Net Receivables | $1.7B | $1.5B | $1.6B | $1.3B | $1.3B |
| Inventory | $3.2B | $4.7B | $6.8B | $6.7B | $5.4B |
| Other Current Assets | $651M | $151M | $469M | $178M | $322M |
| Total Current Assets | $9.1B | $10.8B | $12.4B | $10.6B | $9.6B |
| Property, Plant & Equip. | $2.6B | $2.5B | $2.5B | $2.6B | $2.6B |
| Goodwill & Intangibles | $2.8B | $2.7B | $2.9B | $2.8B | $2.8B |
| Long-Term Investments | $3.2B | $1.6B | $1.2B | $2.1B | $955M |
| Other Non-Current Assets | $1.2B | $1.3B | $1.7B | $729M | $1.1B |
| Total Non-Current Assets | $9.9B | $8.3B | $8.4B | $8.6B | $7.7B |
| Total Assets | $19.0B | $19.1B | $20.8B | $19.2B | $17.3B |
| — Liabilities — | |||||
| Accounts Payable | $239M | $386M | $427M | $302M | $300M |
| Short-Term Debt | $1.9B | $1.9B | $4.1B | $1.9B | $1.8B |
| Deferred Revenue | $862M | $1.1B | $434M | $0 | $0 |
| Other Current Liabilities | $651M | $1.4B | $0 | $2.1B | $831M |
| Total Current Liabilities | $3.6B | $4.8B | $5.6B | $5.0B | $3.7B |
| Long-Term Debt | $3.1B | $2.3B | $2.3B | $1.8B | $1.1B |
| Other Non-Current Liab. | $89M | $147M | $62M | $328M | $34M |
| Total Non-Current Liabilities | $3.7B | $2.8B | $2.8B | $2.2B | $1.4B |
| Total Liabilities | $7.3B | $7.6B | $8.4B | $7.2B | $5.1B |
| — Equity — | |||||
| Common Stock | $1.5B | $1.5B | $1.5B | $1.5B | $1.5B |
| Retained Earnings | $3.7B | $4.2B | $4.3B | $3.4B | $4.6B |
| Accumulated OCI | $0 | -$183M | $0 | $158M | -$1.4B |
| Total Stockholders Equity | $11.6B | $11.4B | $12.3B | $11.9B | $12.1B |
| Total Liabilities & Equity | $19.0B | $19.1B | $20.8B | $19.2B | $17.3B |
| — Key Metrics — | |||||
| Total Debt | $5.6B | $5.7B | $6.5B | $3.8B | $3.0B |
| Net Debt | $2.9B | $2.7B | $4.3B | $1.9B | $1.3B |
| Total Investments | $4.0B | $2.6B | $2.5B | $2.5B | $1.8B |